A study to evaluate changes in function such as walking and/or breathing in subjects taking enzyme replacement therapy (ERT) for late-onset Pompe disease

• Register: EUCTR
• Last refreshed on: 7 January 2019
• Main ID: EUCTR2017-004370-34-BE
• Date of registration: 15/02/2018
• Prospective Registration: Yes
• Primary sponsor: Amicus Therapeutics, Inc.
• Public title: A study to evaluate changes in function such as walking and/or breathing in subjects taking enzyme replacement therapy (ERT) for late-onset Pompe disease
• Scientific title: A Prospective Study in Subjects with Late-onset Pompe Disease who are Currently Being Treated with Enzyme Replacement Therapy
• Date of first enrolment: 09/04/2018
• Target sample size: 125
• Recruitment status: Not Recruiting
• URL: https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-004370-34
• Study type: Interventional clinical trial of medicinal product
• Study design: Controlled: no; Randomised: no; Open: yes; Single blind: no; Double blind: no; Parallel group: no; Cross over: no; Other: yes; Other trial design description: Standard of care therapy; If controlled, specify comparator, Other Medicinial Product: no; Placebo: no; Other: no
• Phase: Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): no Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): yes

Countries of recruitment

Australia, Belgium, Brazil, Canada, Denmark, France, Germany, Hungary, Italy, Japan, Korea, Democratic People's Republic of, Netherlands, Spain, Sweden, Taiwan, United Kingdom, United States

Contacts

• Name: Patient Advocacy
• Affiliation: Amicus Therapeutics, Inc.

• Name: Patient Advocacy
• Affiliation: Amicus Therapeutics, Inc.

Key inclusion & exclusion criteria

Inclusion criteria:
1. Subject has a diagnosis of Pompe disease based on documented deficiency of acid a-glucosidase (GAA) activity and a documented GAA mutation(s) (the gene that encodes GAA).
2. Male and female subjects between 18 years and 75 years, inclusive and >= 50 kg.
3. Subject or legally authorized representative must provide signed informed consent (and assent, if applicable) prior to performing any study-related procedures.
4. Subject must be currently receiving standard-of-care ERT (alglucosidase alfa) at the recommended dose (approximately 20 mg/kg dose) every other week and for the past 2 years or more.
5. Subject must be able to perform pulmonary testing and muscle function testing in a seated position.
6. Subjects must have an upright forced vital capacity (FVC) within 35 to 90% of predicted normal (NHANES III reference values), based on the higher of the screening or baseline value, if their 6-minute walk distance (6MWD) is > 200 m. Subject must have an upright FVC within 40 to 90% of predicted normal (NHANES III reference values), based on the higher of the screening or baseline value, if their 6MWD is
= 200 m. If FVC is between 80 and 90% of predicted normal, the subject may enter the
study if the percent predicted FVC value drops by 10% predicted or more in supine position.
7. Subject is able to walk at least 100 m in the 6MWT and the assessment is noted as valid.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 90
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 35

Exclusion criteria:
1. Subject has received any investigational therapy or pharmacological treatment for Pompe disease, other than alglucosidase alfa, within 30 days or 5 half lives, whichever is shorter, prior to the Baseline Visit or is anticipated to do so during the course of the study.
2. Subject is on any of the following prohibited medications within 30 days or 5 half lives, whichever is shorter, prior to baseline, or is anticipated to do so during the course of the study:
• miglitol (eg, Glyset)
• miglustat (eg, Zavesca)
• acarbose (eg, Precose, Glucobay)
• voglibose (eg, Volix, Vocarb, Volibo)
3. Subject requires use of invasive or non-invasive ventilatory support for > 6 hours a day while awake.
4. Subject has a medical or any other extenuating condition or circumstance that may, in the opinion of the investigator, pose an undue safety risk to the subject or compromise his/her ability to comply with protocol requirements. This includes clinical depression
(as diagnosed by a psychiatrist or other mental health professional) with uncontrolled
or poorly controlled symptoms.
5. Subject is breastfeeding, or is pregnant or planning to become pregnant within the next
2 years.
6. Other exclusion criteria according to the Lumizyme/Myozyme instructions for use.


Age minimum:
Age maximum:
Gender:
Female: yes
Male: yes

Health Condition(s) or Problem(s) studied

Late-onset Pompe disease (LOPD) in subjects receiving standard-of-care enzyme replacement therapy (ERT)
MedDRA version: 20.0 Level: LLT Classification code 10075702 Term: Pompe's disease late onset System Organ Class: 100000004850

Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]

Intervention(s)

Pharmaceutical Form: Powder for solution for infusion
INN or Proposed INN: ALGLUCOSIDASE ALFA
CAS Number: 420784-05-0
Concentration unit: mg/kg milligram(s)/kilogram
Concentration type: equal
Concentration number: 20-

Primary Outcome(s)

Secondary Objective: Not Applicable

Timepoint(s) of evaluation of this end point: Parameters throughout the study. Historical data for these parameters will also be collected.

Main Objective: The purpose of the study is to evaluate changes in key clinical outcome measures (eg, motor, respiratory, fatigue) in adult subjects with late-onset Pompe disease (LOPD) receiving standard-of-care enzyme replacement therapy (ERT). Additionally, information gained may be used in the design and conduct of future studies in LOPD subjects

Primary end point(s): Evaluation of changes in key clinical outcome measures (eg, motor, respiratory, fatigue) in adult late-onset Pompe disease (LOPD) subjects receiving standard-of-care enzyme replacement therapy (ERT).

Secondary Outcome(s)

Timepoint(s) of evaluation of this end point: Parameters throughout the study. Historical data for these parameters will also be collected.

Secondary end point(s): Gained information gained may be used in the design and conduct of future studies in LOPD subjects.

Secondary ID(s)

POM-003

Source(s) of Monetary Support

Amicus Therapeutics, Inc.